Empirical Financial Services, LLC D.B.A. Empirical Wealth Management Recursion Pharmaceuticals, Inc. Transaction History

Empirical Financial Services, LLC D.B.A. Empirical Wealth Management

$3.55 Billion
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2023 Nov 02, 2023	BUY	$6.59 - $15.86 $106,283 - $255,790	16,128 Added 120.18%	29,548 $226,000
Q2 2023 Aug 11, 2023	BUY	$4.56 - $9.94 $61,195 - $133,394	13,420 New	13,420 $100,000

Others Institutions Holding RXRX

# of Institutions

289

Shares Held

242M

Call Options Held

1.35M

Put Options Held

2.32M

Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl

32.8M
Shares

$214 Million
2.05% of portfolio
Baillie Gifford & CO

25.2M
Shares

$165 Million
0.13% of portfolio
Vanguard Group Inc Valley Forge, PA

24.3M
Shares

$159 Million
0.0% of portfolio
Black Rock Inc. New York, NY

17.3M
Shares

$113 Million
0.0% of portfolio
Ra Capital Management, L.P. Boston, MA

15.4M
Shares

$100 Million
1.41% of portfolio

View Full List

About RECURSION PHARMACEUTICALS, INC.

Ticker RXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 180,480,000
Market Cap $1.18B
Description
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...

More about RXRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Empirical Financial Services, LLC D.B.A. Empirical Wealth Management, based on Form 13F filings with the SEC.

News

Stay updated on Empirical Financial Services, LLC D.B.A. Empirical Wealth Management with notifications on news.

Account